Skip to Content
You are currently on the new version of our website. Access the old version .

1 Result Found

  • Article
  • Open Access
5 Citations
3,358 Views
18 Pages

13 January 2022

Hormonal therapies for prostate cancer target the androgen receptor (AR) ligand-binding domain (LBD). Clinical development for inhibitors that bind to the N-terminal domain (NTD) of AR has yielded ralaniten and its analogues. Ralaniten acetate is wel...

(This article belongs to the Special Issue Novel Therapeutics for Genitourinary Tumors)